Product Search Results

35 products match your search.
Calcipotriene and Betamethasone Dipropionate Ointment, 0.005%/0.064%
Generic to: Taclonex®
Calcitriol Ointment, 3 mcg/g
Generic to: Vectical® Ointment
Calcium Acetate Tablets, USP
Generic to: Eliphos®
Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets, 5mg/120mg
Compare to the Active Ingredient of: Zyrtec-D®
Cetirizine Hydrochloride Syrup, 1mg/mL
Generic to: Zyrtec® Syrup
Cetirizine Hydrochloride Tablets, 10 mg
Compare to the Active Ingredient of: Zyrtec®
Children's Acetaminophen Oral Suspension 160 mg per 5 mL Cherry Flavor
Compare to the Active Ingredient of: Children's Tylenol® Oral Suspension
Children's Acetaminophen Oral Suspension 160 mg per 5 mL Grape Flavor
Compare to the Active Ingredient of: Children's Tylenol® Oral Suspension
Children's Cetirizine Hydrochloride Oral Solution 1mg/mL
Compare to the Active Ingredient of: Children's Zyrtec®
Children's Ibuprofen Oral Suspension 100 mg per 5 mL (teaspoonful) Berry Flavor
Compare to the Active Ingredient of: Children's Motrin®
Children's Ibuprofen Oral Suspension 100 mg per 5 mL (teaspoonful) Grape Flavor
Compare to the Active Ingredient of: Children's Motrin®
Children's Ibuprofen Oral Suspension 100 mg per 5 mL Bubble Gum Flavor
Compare to the Active Ingredient of: Children's Motrin®
Ciclopirox Gel, 0.77%
Generic to: LOPROX®
Ciclopirox Olamine Cream USP, 0.77%
Generic to: Loprox®
Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion)
Generic to: Loprox® Topical Suspension
Ciclopirox Shampoo, 1%
Generic to: Loprox®
Ciclopirox Topical Solution, 8%
Generic to: Penlac®
Clindamycin and Benzoyl Peroxide Topical Gel, 1%/5%
Generic to: Benzaclin®
Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/5%
Generic to: DUAC® Gel
Clindamycin Phosphate Foam, 1%
Generic to: Evoclin®
Clindamycin Phosphate Topical Solution USP, 1%
Generic to: Cleocin-T®
Clindamycin Phosphate Topical Solution USP, 1% (Pledgets)
Generic to: Cleocin-T®
Clindesse®
(clindamycin phosphate) Vaginal Cream, 2%
Clobetasol Propionate Foam (Emollient Formulation) 0.05%
Generic to: Olux-E®
Clobetasol Propionate Foam, 0.05%
Generic to: Olux®
Clobetasol Propionate Gel, 0.05%
Generic to: Temovate®
Clobetasol Propionate Lotion 0.05%

Clobetasol Propionate Shampoo, 0.05%
Generic to: Clobex® Shampoo
Clobetasol Propionate Topical Solution USP, 0.05% Spray
Generic to: Clobex® Spray
Clotrimazole Cream USP, 1%
Compare to the Active Ingredient of: Lotrimin® AF
Clotrimazole Lozenges
Generic to: Mycelex® Troches
COLOCORT® Hydrocortisone Rectal Suspension USP (Retention)
Generic to: Cortenema®
Compound Benzoin Tincture USP

COMPro® Prochlorperazine Suppositories, USP 25 mg

Cyclosporine Injection, USP 250 mg/5 mL (50 mg/mL)

Important Safety Information
  • Alogliptin is contraindicated in patients with a history of serious hypersensitivity reaction to alogliptin-containing products such as anaphylaxis, angioedema, or severe cutaneous adverse reactions.
  • Acute pancreatitis: There have been postmarketing reports of acute pancreatitis. If pancreatitis is suspected, promptly discontinue Alogliptin.
  • Hypersensitivity: There have been postmarketing reports of serious hypersensitivity reactions in patients treated with Alogliptin such as anaphylaxis, angioedema or severe cutaneous adverse reactions. In such cases, promptly discontinue Alogliptin, assess for other potential causes, institute appropriate monitoring and treatment, and initiate alternative treatment for diabetes. Use caution in a patient with a history of angioedema with another DPP-4i because it is unknown whether such patients will be predisposed to angioedema.
  • Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal. Causality cannot be excluded. Baseline liver test panel is recommended. If liver injury is detected, promptly interrupt Alogliptin and assess patient for probable cause, then treat cause if possible, to resolution or stabilization. Do not restart Alogliptin if liver injury is confirmed and no alternative etiology can be found.
  • Hypoglycemia: Insulin and insulin secretagogues are known to cause hypoglycemia. A lower dose of the insulin or insulin secretagogue may be required to minimize the risk when used in combination with Alogliptin.
  • Arthralgia: Severe and disabling arthralgia has been reported in patients taking DPP-4 inhibitors. Consider as a possible cause for severe joint pain and discontinue drug if appropriate.
  • Macrovascular outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Alogliptin or any other anti-diabetic drug.
  • Most common adverse reactions (4% of patients treated with Alogliptin 25 mg and more frequently than in patients who received placebo) were nasopharyngitis (4.4%), headache (4.2%), and upper respiratory tract infection (4.2%).

Patients taking Alogliptin should contact their health care professionals right away if they develop signs and symptoms of heart failure such as:

  • Unusual shortness of breath during daily activities
  • Trouble breathing when lying down
  • Tiredness, weakness, or fatigue
  • Weight gain with swelling in the ankles, feet, legs, or stomach Patients should not stop taking their medicine without first talking to their health care professionals.

Patients should not stop taking their medicine without first talking to their health care professionals.

Indication

Alogliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Alogliptin is not for treatment of type 1 diabetes or diabetic ketoacidosis.

Please see Full Prescribing Information, including Medication Guide for Alogliptin.


©2016 Perrigo Company, plc

Cookie Policy

By using our site you consent to the use of cookies in accordance with the terms of our privacy policy.

Hide this message
Perrigo on Facebook Perrigo on Twitter Perrigo on YouTube Perrigo on LinkedIn Perrigo RSS